How to Distribute Active Substances Under EU GDP
Apply the distribution rules written for active substances, not the finished-product ones.
What a how-to is not
A how-to is SPEQ’s practitioner method, not a procedure. It does not replace your own SOP, it is not a validated approach, and the judgement calls in it belong to your quality unit.
The EU publishes separate distribution guidelines for active substances and for finished medicinal products, and they are not interchangeable. Active substance distribution sits between manufacture and the medicinal product manufacturer, where the customer is a factory rather than a pharmacy, quantities are bulk, and the practical risks are contamination, mislabelling and undetected re-packaging in the chain.
- 1
Confirm which guideline governs the material you handle
Active substances follow their own distribution guideline; finished medicinal products follow the other. Excipients are different again and are not covered by either. Applying the finished-product guideline to bulk active substance produces controls aimed at the wrong risks.
- 2
Register the activity where registration is required
Importers, manufacturers and distributors of active substances are subject to registration obligations in their member state. Operating as an unregistered distributor is a status problem that no amount of good practice downstream corrects.
- 3
Preserve traceability back to the original manufacturer
Documentation must allow the material to be traced to the manufacturing site, through every intermediary. Chains where a broker has obscured the origin are precisely how contaminated material has reached medicinal products historically.
- 4
Control repackaging, relabelling and container integrity
Where material is repackaged or relabelled, the operation is controlled, documented and does not obscure the original identity. Container closure integrity in transport and storage is a contamination control here rather than a stability one.
- 5
Handle certificates of analysis as evidence, not as decoration
A certificate must be attributable to a batch from a known manufacturer, and the receiving manufacturer will test against it. Passing on a certificate that cannot be tied to the material supplied is the mechanism through which substitution has succeeded.
- 6
Apply the veterinary rules where the material is for veterinary use
Active substances for veterinary medicinal products have their own distribution requirements in EU law. The material may be chemically identical while the applicable instrument differs, which is not something a specification will tell you.
- !The finished-product distribution guideline applied to bulk active substance.
- !Distribution or import operated without the member-state registration the activity requires.
- !A broker in the chain obscuring the original manufacturing site, breaking traceability.
- !Certificates of analysis passed on without being tied to the batch actually supplied.
How to Distribute Active Substances Under EU GDP: frequently asked questions
Common questions on distribute active substances under eu gdp.
Why are there separate guidelines at all?
Because the risks differ. Finished-product distribution protects against falsification, mishandling and diversion on the way to a patient. Active substance distribution protects a manufacturing input against contamination, substitution and loss of traceability on the way to a factory. The controls that matter are not the same ones.
Do these guidelines cover excipients?
No. Excipients are governed separately, which surprises people because they sit alongside active substances in the same formulation and often arrive from the same kind of supplier. Assuming the active substance guideline covers them leaves the excipient supply chain governed by nothing you have applied.
What makes traceability the central control here?
Because the material will be built into a medicinal product and cannot be recalled from a patient once it has been. When a contamination signal emerges, the only way to scope it is to trace batches back to the manufacturing site through every intermediary — and a broken chain makes the scope unknowable.